Literature DB >> 6468469

Effect of indapamide on renal plasma flow, glomerular filtration rate and arginine vasopressin in plasma in essential hypertension.

E B Pedersen, H Danielsen, E S Spencer.   

Abstract

Renal plasma flow (RPF), glomerular filtration rate (GFR), arginine vasopressin in plasma (AVP), free water clearance (CH2O) and blood pressure (BP) were determined in 11 patients with essential hypertension at the end of 3 consecutive periods of observation each of 6 of weeks duration; indapamide 2.5 mg daily was given in period 2 and placebo in periods 1 and 3. RPF and GFR were reduced by 9% and BP by 9%/14% supine and 14%/12% standing during indapamide treatment. Changes in renal haemodynamics were not correlated with those in BP. AVP was not significantly altered by indapamide and was not correlated with BP. Indapamide reduced CH2O possibly due to the reduction in GFR. It is concluded that indapamide evidently induces redistribution of the cardiac output, with enhanced muscle blood flow and reduced renal perfusion, and that AVP does not seem to be involved in blood pressure regulation in mild to moderate essential hypertension under basal conditions.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6468469     DOI: 10.1007/bf00543482

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  19 in total

1.  Glomerular filtration rate, renal plasma flow and filtration fraction in living donors before and after nephrectomy.

Authors:  P E Skov; H E Hansen
Journal:  Acta Med Scand       Date:  1974 Jan-Feb

2.  Glomerular filtration rate and renal plasma flow in short-term and long-term juvenile diabetes mellitus.

Authors:  C E Mogensen
Journal:  Scand J Clin Lab Invest       Date:  1971-09       Impact factor: 1.713

Review 3.  Some aspects of kidney function, the renin-aldosterone system and sympathetic activity in essential hypertension.

Authors:  E B Pedersen
Journal:  Acta Med Scand Suppl       Date:  1980

4.  Role of vasopressin in cardiovascular homeostasis and hypertension.

Authors:  C I Johnston; M Newman; R Woods
Journal:  Clin Sci (Lond)       Date:  1981-12       Impact factor: 6.124

5.  Renal hemodynamic changes during long-term antihypertensive therapy.

Authors:  S E Warren; D T O'Connor; I M Cohen; J A Mitas
Journal:  Clin Pharmacol Ther       Date:  1981-03       Impact factor: 6.875

6.  Vasopressin and blood pressure.

Authors:  F C Bartter
Journal:  N Engl J Med       Date:  1981-04-30       Impact factor: 91.245

7.  Development and clinical application of a new method for the radioimmunoassay of arginine vasopressin in human plasma.

Authors:  G L Robertson; E A Mahr; S Athar; T Sinha
Journal:  J Clin Invest       Date:  1973-09       Impact factor: 14.808

8.  Vasopressin elevation in essential hypertension and increased responsiveness to sodium intake.

Authors:  A W Cowley; W C Cushman; E W Quillen; M M Skelton; H G Langford
Journal:  Hypertension       Date:  1981 May-Jun       Impact factor: 10.190

9.  Increased renal excretion of arginine-vasopressin during mild hydropenia in young men with mild essential benign hypertension.

Authors:  A M Khokhar; J D Slater
Journal:  Clin Sci Mol Med Suppl       Date:  1976-12

10.  Vasopressor role of ADH in the pathogenesis of malignant DOC hypertension.

Authors:  J Möhring; B Möhring; M Petri; D Haack
Journal:  Am J Physiol       Date:  1977-03
View more
  21 in total

1.  Long-term treatment of nocturnal enuresis with desmopressin. A follow-up study.

Authors:  U B Knudsen; S Rittig; J P Nørgaard; J B Lundemose; E B Pedersen; J C Djurhuus
Journal:  Urol Res       Date:  1991

2.  Sustained release verapamil in renal hypertension.

Authors:  H Eiskjaer; E B Pedersen; L M Rasmussen; B Jespersen
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

3.  Renal hemodynamic response to ureteral obstruction during converting enzyme inhibition.

Authors:  J Frøkiaer; J C Djurhuus; M Nielsen; E B Pedersen
Journal:  Urol Res       Date:  1996

4.  Neurohormonal activation late after cavopulmonary connection.

Authors:  V E Hjortdal; E V Stenbøg; H B Ravn; K Emmertsen; K T Jensen; E B Pedersen; K H Olsen; O K Hansen; K E Sørensen
Journal:  Heart       Date:  2000-04       Impact factor: 5.994

5.  Effect of nebivolol on renal nitric oxide availability and tubular function in patients with essential hypertension.

Authors:  Frank H Mose; Janni M Jensen; Safa Therwani; Jesper Mortensen; Annebirthe B Hansen; Jesper N Bech; Erling B Pedersen
Journal:  Br J Clin Pharmacol       Date:  2015-06-05       Impact factor: 4.335

6.  Renal and hormonal effects and tolerance of an ANP analogue in healthy man.

Authors:  H Eiskjaer; M Schmiegelow; B Jespersen; I N Tietze; J D Jensen; S S Sørensen; K Thomsen; E B Pedersen
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

7.  Effect of captopril on renal haemodynamics and the renin-angiotensin-aldosterone and osmoregulatory systems in essential hypertension.

Authors:  O O Thomsen; H Danielsen; S S Sørensen; E B Pedersen
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

8.  Identification of 13 new mutations in the vasopressin-neurophysin II gene in 17 kindreds with familial autosomal dominant neurohypophyseal diabetes insipidus.

Authors:  S Rittig; G L Robertson; C Siggaard; L Kovács; N Gregersen; J Nyborg; E B Pedersen
Journal:  Am J Hum Genet       Date:  1996-01       Impact factor: 11.025

9.  Effects of atorvastatin on systemic and renal NO dependency in patients with non-diabetic stage II-III chronic kidney disease.

Authors:  Frank Holden Mose; Thomas Larsen; Janni Majgaard Jensen; Annebirthe Bo Hansen; Jesper Nørgaard Bech; Erling Bjerregaard Pedersen
Journal:  Br J Clin Pharmacol       Date:  2014-10       Impact factor: 4.335

10.  Effect of verapamil on renal plasma flow, glomerular filtration rate and plasma angiotensin II, aldosterone and arginine vasopressin in essential hypertension.

Authors:  S S Sørensen; O O Thomsen; H Danielsen; E B Pedersen
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.